Title: Mitochondrial fission - a drug target for cytoprotection or cytodestruction?
Authors: Rosdah, AA
Holien, JK
Delbridge, LMD
Dusting, GJ
Lim, SY
Issue Year: 2016
Publisher JOHN WILEY & SONS LTD
Series Pharmacol. Res. Perspect.:
Abstract Mitochondria are morphologically dynamic organelles constantly undergoing processes of fission and fusion that maintain integrity and bioenergetics of the organelle: these processes are vital for cell survival. Disruption in the balance of mitochondrial fusion and fission is thought to play a role in several pathological conditions including ischemic heart disease. Proteins involved in regulating the processes of mitochondrial fusion and fission are therefore potential targets for pharmacological therapies. Mdivi-1 is a small molecule inhibitor of the mitochondrial fission protein Drp1. Inhibiting mitochondrial fission with Mdivi-1 has proven cytoprotective benefits in several cell types involved in a wide array of cardiovascular injury models. On the other hand, Mdivi-1 can also exert antiproliferative and cytotoxic effects, particularly in hyperproliferative cells. In this review, we discuss these divergent effects of Mdivi-1 on cell survival, as well as the potential and limitations of Mdivi-1 as a therapeutic agent.
URI: https://publications.svi.edu.au/publications/6644
Other Identifiers 10.1002/prp2.235
Publication type Review